Turnstone Biologics Corp.
TSBX
$0.35
$0.0319.72%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -100.00% | -73.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -100.00% | -73.66% |
| Cost of Revenue | -3.48% | -1.09% | -15.60% | -44.67% | -48.13% |
| Gross Profit | -81.12% | -222.28% | -320.66% | -818.87% | -245.00% |
| SG&A Expenses | -8.16% | -1.30% | 0.55% | 6.60% | -2.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.29% | -0.39% | -8.59% | -17.23% | -22.51% |
| Operating Income | -29.72% | -61.79% | -72.60% | -561.85% | -129.85% |
| Income Before Tax | -27.60% | -43.51% | -46.13% | -314.58% | -80.78% |
| Income Tax Expenses | 112.94% | -808.49% | -2,671.43% | -582.05% | -302.84% |
| Earnings from Continuing Operations | -28.33% | -41.97% | -45.76% | -312.66% | -79.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.33% | -41.97% | -45.76% | -312.66% | -79.02% |
| EBIT | -29.72% | -61.79% | -72.60% | -561.85% | -129.85% |
| EBITDA | -33.06% | -69.06% | -82.32% | -859.16% | -159.63% |
| EPS Basic | 78.65% | 82.81% | 85.44% | 36.41% | -22.05% |
| Normalized Basic EPS | 65.34% | 70.48% | 78.54% | -192.07% | 2.21% |
| EPS Diluted | 78.65% | 82.81% | 85.44% | 36.74% | -21.16% |
| Normalized Diluted EPS | 65.34% | 70.48% | 78.54% | -135.66% | 10.26% |
| Average Basic Shares Outstanding | 100.47% | 258.10% | 690.08% | 533.95% | 362.67% |
| Average Diluted Shares Outstanding | 100.47% | 258.10% | 690.08% | 506.55% | 341.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |